Research programme: metapneumovirus infection therapeutics - Inhalon Biopharma
Alternative Names: Metapneumovirus infection therapeutics - Inhalon BiopharmaLatest Information Update: 28 Jun 2025
At a glance
- Originator Inhalon Biopharma
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Metapneumovirus infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for research development in Metapneumovirus-infections in USA (Inhalation)
- 01 Nov 2023 Human Metapneumovirus (hMPV) antibodies licensed to Inhalon Biopharma
- 01 Jun 2021 Research programme: metapneumovirus infection therapeutics - Inhalon Biopharma is available for licensing as of 01 Jun 2021. https://www.inhalon.com/contact